Actuate Therapeutics, Inc..
ACTU.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products
Actuate Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapeutics for cancers that have become resistant to standard treatments. Their primary focus is on developing therapies that modulate cellular stress responses to selectively...Show More
Better Health for All
20
Actuate Therapeutics' core product, elraglusib, demonstrates transformative health benefits for difficult-to-treat cancers.
1
In metastatic pancreatic cancer trials, it reduced the risk of death by 37-43%
2
and doubled the one-year survival rate (44.1% vs 22.3%).
3
It also showed complete responses in metastatic melanoma
4
and in pediatric patients (ages 3-21) with relapsed/refractory Ewing sarcoma and neuroblastoma,
5
diseases with limited treatment alternatives and low survival rates.
6
The company's entire business is devoted to developing these therapies. Elraglusib has a favorable risk-benefit profile,
7
with similar rates of treatment-emergent and serious adverse events in both treatment and control arms.
8
While transient visual impairment was noted as a major adverse event,
9
it was mild to moderate with no permanent changes to eye structure or vision.
10
The company focuses on vulnerable populations, specifically pediatric patients (ages 3-21) with relapsed/refractory cancers.
11
Actuate Therapeutics is a clinical-stage biopharmaceutical company
12
developing elraglusib, a novel GSK-3β inhibitor,
13
and is initiating a pivotal Phase 3 study based on Phase 1/2 data.
14
Clinical trials are randomized,
15
open-label, multicenter studies
16
with defined inclusion criteria, including for pediatric patients.
17
Fair Money & Economic Opportunity
0
Actuate Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing cancer therapeutics.
1
The company's core business does not involve lending, insuring, moving, or storing money, nor does it offer consumer financial products or services.
2
Therefore, all KPIs related to fair money and economic opportunity, which are designed for financial institutions, are not applicable to Actuate Therapeutics.
Fair Pay & Worker Respect
0
Actuate Therapeutics received an average employee rating of 3.6 out of 5 stars from 84 reviews.
1
As of December 31, 2024, the company had 10 employees.
2
Which is considered too small a workforce for meaningful turnover metrics.
Fair Trade & Ethical Sourcing
0
No evidence available to assess Actuate Therapeutics, Inc. on Fair Trade & Ethical Sourcing.
Honest & Fair Business
0
No evidence available to assess Actuate Therapeutics, Inc. on Honest & Fair Business.
Kind to Animals
-60
Actuate Therapeutics' related studies utilize in vitro cell growth assays, quantitative chromosome alignment assays, and cell-based assays as alternatives in initial stages, but these are used in addition to in vivo animal models for efficacy.
1
The company conducts preclinical studies on animals, including rats and dogs, to assess drug safety, with specific studies using male Balb/c immunodeficient nude mice, NOD/SCID mice, and NSG male mice.
2
Animal toxicology studies for elraglusib involved doses up to 50 mg/kg in rats and 20 mg/kg in dogs.
3
The company's animal studies are approved by various Institutional Animal Care and Use Committees (IACUCs) and Animal Welfare Ethics Review Boards, and conducted in accordance with UK Home Office regulations and state regulations.
4
However, the company's studies also used fetal calf serum for cell culture, with no evidence of substitution.
5
There is no evidence of Actuate Therapeutics actively engaging in animal welfare policy improvement or advocacy, nor any participation in multi-stakeholder initiatives for animal-free testing standards.
6
No War, No Weapons
0
The provided articles do not contain any specific data points or information relevant to Actuate Therapeutics, Inc.'s involvement with arms manufacturing, military contracts, or conflict facilitation.
1
All articles explicitly state that no data relevant to the 'No War, No Weapons' value can be extracted.
2
Planet-Friendly Business
0
No specific, concrete data points relevant to any of the 'Planet-Friendly Business' KPIs were found in the provided articles. The articles primarily focus on the company's mission, science, pipeline, and partnering opportunities related to cancer treatment, and explicitly state they do not contain environmental, social, or governance (ESG) performance data.
1
Respect for Cultures & Communities
0
The provided articles primarily focus on Actuate Therapeutics' clinical trial results, regulatory milestones, and financial performance. They detail drug development, efficacy data, regulatory designations (Orphan Drug, Fast Track), and financial activities like IPOs and capital raising.
1
While one article mentions the company "integrates and communicates with the community in their cancer of interest, both on the investigator and clinician side as well as on the patient side,"
2
this is a general statement and does not provide specific, concrete data points for any of the quantitative or qualitative KPIs related to formal partnerships, community investment, cultural incidents, impact assessments, local employment, grievance mechanisms, or other metrics concerning the company's respect for cultures and communities. Therefore, no specific evidence was found to score any of the KPIs.
Safe & Smart Tech
0
No specific, concrete evidence was found across the provided articles to assess Actuate Therapeutics, Inc. against any of the Key Performance Indicators for the 'Safe & Smart Tech' value. Information regarding data protection, cybersecurity investment, AI ethics, privacy certifications, or regulatory compliance related to privacy (e.g., GDPR, CCPA) was not available.
1
Zero Waste & Sustainable Products
0
The provided article discusses general best practices for managing pharmaceutical hazardous waste and explicitly states that no data relevant to Actuate Therapeutics, Inc. or specific zero waste and sustainable product metrics is presented.
1
Therefore, no evidence was found to assess any of the KPIs for this company under the 'Zero Waste & Sustainable Products' value.